FectoVIR®-LV

Lentiviral vectors are recognized to be the carrier of choice for allogenic or autologous cell therapies (such as CAR-T) because of its capacity to permanently integrate viral genome into host cell DNA. To produce those vectors, cell therapy producers generally use a transient transfection system that is scaled-up during process development phases. FectoVIR®-LV is the next generation of transfection reagent, free of animal component, designed to improve LV productivity in HEK-293 cell systems. FectoVIR®-LV is made for large scale manufacturing with reduction of the complexation volume and increased complex stability. The FectoVIR®-LV benefits allow to increase number of doses produced per batch to treat more patient, while decreasing LV manufacturing costs. 

Take advantage of the complementary DOE service to fast-track optimization of lentivirus production with FectoVIR®-LV. 

Key Benefits:

Productivity: Reach the highest Lentiviral vectors titers in suspension systems.

Cost-Effectiveness: Reduce your cost per batch with high titers and low DNA consumption.

Scalability: Produce at large scale with low complexation volume and long complex stability.

Time-Saving: Use DOE service to help you optimizing your process in a record time.